Quantification of the Potential Impact of Cost-effectiveness Thresholds on Dutch Drug Expenditures Using Retrospective Analysis

Background: Other than the UK, The Netherlands has no formal threshold for cost-per-QALY values defined yet. For example, a cutoff value at 20,000 per QALY is sometimes mentioned in various discussions, however it has no formal status at all. Yet, since 2005, all new innovative do have to go through a cost-effectiveness evaluation though, with the assessment being focused on the methodology rather than on the exact cost-per-QALY outcome. Objective: Our objective was to estimate the potential impacts on Dutch drug expenditures had a formal threshold been applied in recent years. Methods: We ana... Mehr ...